DCE CT/MRI Scanning Study in Patients With Solid Tumours (AstraZeneca and Royal Marsden Hospital Imaging Study)

Model scores of the 29,894 trials active now.

Model score 12% for any early termination, 2% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 16% of the time (1,938 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2010-11-30. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: mrictimagingpatientsscan
  Phrases that lowered it: prostateadvanced solidbloodhormoneopen label
• Primary purpose: not given (lowers risk) · Design
• Accepts healthy volunteers: No (raises risk) · Who can join
• Sponsor's past termination rate: 6.5% (lowers risk) · Sponsor's track record
• Phase: 1 (lowers risk) · Design
• Disease area, cancer: Yes (raises risk) · Disease area
• Responsible party: not given (raises risk) · Design
• Design: single group (raises risk) · Design
• Drug's FAERS reports marked serious: 100% (raises risk) · Drug's FDA history
• Drug's FAERS reports with a death: 0% (lowers risk) · Drug's FDA history
• Minimum age: 18 (raises risk) · Who can join
• Trials the sponsor started in the prior 2 years: 267 (raises risk) · Sponsor's track record
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Has a data monitoring committee: No (lowers risk) · Design
• Sponsor's past trials: 448 (lowers risk) · Sponsor's track record
• Maximum age: not given (raises risk) · Who can join
• Keywords listed: 8 (raises risk) · Design
• Drug's FAERS reports before start: 8 (lowers risk) · Drug's FDA history
• Number of arms: 1 (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• RGD-PET-CT in Cancer Angiogenesis NCT01492192 · started 2013 · scored riskier than 54% of active trials terminated
• FOLFIRI and Sunitinib in Metastatic Colorectal Cancer NCT00806663 · started 2008 · scored riskier than 58% of active trials completed
• 18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy NCT01806675 · started 2013 · scored riskier than 86% of active trials completed
• Performance of Elucirem in DSC-MRI Perfusion of Brain Gliomas NCT06057168 · started 2023 · scored riskier than 54% of active trials completed
• CEST- Glucose Enhanced MRI for Metastatic Brain Tumours NCT02796729 · started 2016 · scored riskier than 13% of active trials terminated

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.